TARGID

Host target identification of anti-virulence drugs

Coordinatore	ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE    more  Organization address address: BATIMENT CE 3316 STATION 1 city: LAUSANNE postcode: 1015 contact info Titolo: Prof. Nome: Stewart Cognome: Cole Email: send email Telefono: +41 21 693 1851 Fax: +41 21 693 1790
Nazionalità Coordinatore	Switzerland [CH]
Totale costo	192˙622 €
EC contributo	192˙622 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2012-IEF
Funding Scheme	MC-IEF
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-01-01   -   2015-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE  Organization address address: BATIMENT CE 3316 STATION 1 city: LAUSANNE postcode: 1015 contact info Titolo: Prof. Nome: Stewart Cognome: Cole Email: send email Telefono: +41 21 693 1851 Fax: +41 21 693 1790	CH (LAUSANNE)	coordinator	192˙622.20

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'While short course chemotherapy for drug-susceptible tuberculosis (TB) remains effective, it is relatively inefficient by modern pharmaceutical standards and universally menaced by the dissemination of multidrug-resistant (MDR), extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis (M.tb) and synergy with the HIV/AIDS pandemic. Since one third of the world’s population is latently infected with M.tb, successful anti-TB drugs must be able to eliminate persistent bacilli from the reservoir, which makes TB therapy more challenging. Most of the current antibiotics typically kill M.tb rather than targeting bacterial systems important in the virulence of the bacteria and manipulation of the host-specific biochemical pathways. Whereas normally the host immune system is able to destroy invading bacilli, M.tb developed a wide palette of strategies to avoid bactericidal host responses. The major and most studied virulence mechanism of the tuberculosis pathogen is the ESX-1 system, a type VII secretion system which clearly plays an important role in the pathogenicity and the host-pathogen interaction. The ESX-1 system modulates the host defence through different ways like phagosome maturation arrest, inhibition of TLR signalling in macrophages, macrophage apoptosis induction, and interaction with laminin. The here proposed project forms part of a multidisciplinary anti-virulence drug discovery program focusing on the identification of important host cell signalling pathways that are involved in the pathogenesis, entry and intracellular survival of M.tb. Anti-virulence drugs inhibit bacterial targets that interfere with host cell defence pathways during infection or block host signalling pathways modulated by the bacteria, thus defending the host from the pathogen. This novel strategy of anti-virulence drug discovery is a potential alternative to antibiotics, which may be used in combination therapies to shorten TB treatment and prevent resistance.'